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Background
HIV continues to be a serious public health issue in 
the European Union/European Economic Area (EU/
EEA) and, despite concerted prevention efforts, the 
number of new HIV diagnoses reported each year has 
remained largely unchanged over the last decade [1]. 
The European region is increasing its efforts to reach 
the 90–90–90 targets advocated by the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) [2]. One of 
the major challenges many European countries face is 
the high proportion of undiagnosed people living with 
HIV [3] and the high rates of late diagnosis [4,5]. In 
the past years, testing programmes have improved in 
terms of their accessibility and coverage, yet it remains 
difficult to monitor and evaluate the performance of 
testing programmes at all levels as a consequence of 
significant gaps in the data available on testing ser-
vices [4,6].
In October 2016, the European Centre for Disease 
Prevention and Control (ECDC) convened an expert 
consultation, attended by representatives from a range 
of constituencies (national institutions, community 
organisations, healthcare workers) from 14 Member 
States and international organisations, to explore how 
to strengthen monitoring of HIV testing in the EU/EEA. 
The consultation’s aims were to (i) share experiences 
on how HIV testing is currently monitored, (ii) reflect on 
the need, scope and feasibility of a common approach 
to monitor HIV testing and (iii) formulate recommenda-
tions on how to improve the monitoring of HIV testing 
in the EU/EEA.
Strategic information and targeted HIV 
testing: what is needed?
Representatives of different constituencies from four 
countries made paired presentations on the need for 
and the use of strategic information at country level. 
For each country there were unique positions on the 
challenges of collecting and using strategic information 
but a clear consensus emerged that more and better 
national data were needed to monitor and implement 
an effective HIV testing strategy.
Susan Cowan (Statens Serum Institut, Denmark) and 
Per Slaaen Kaye (AIDS-Fondet) emphasised the impor-
tance of pushing beyond existing approaches to HIV 
testing in order to reduce the number of undiagnosed 
people. They noted that alternative approaches to test-
ing, including, for example, home testing, are likely 
to be even more difficult to monitor than existing 
approaches. Cost-per-test and cost-per-case-detected 
is considered an important element in the assess-
ment of testing approaches. Nevertheless, it was noted 
that the cost-per-case of finding new cases is likely 
to increase as the number of undiagnosed people 
declines.
Florence Lot (Agence nationale de santé publique, 
France) and Richard Stranz (AIDES) made comple-
mentary presentations about the current situation in 
France. They shared concerns about the large number 
of undiagnosed HIV cases and the high rates of undiag-
nosed prevalence among three populations: men who 
have sex with men (MSM), heterosexual women born 
abroad and heterosexual men born abroad. Intense 
community outreach and localised testing are being 
implemented in France to improve knowledge and test-
ing uptake among these key populations.
Olivia Castillo Soria (Ministry of Health, Social Services 
and Equality, Spain) and Jordi Casabona (Centre 
d’Estudis Epidemiològics sobre les ITS i la Sida de 
Catalunya) described the importance of community HIV 
testing in Spain and presented an ongoing ministerial 
initiative to map and geo-reference community-based 
testing sites in the country and collect standardised 
information on HIV community testing programmes 
like number of test and result, testing and counselling 
and linkage to care. The long-standing experience of 
the HIV-DEVO Project [7] in Catalonia was presented as 
an example of a successful approach to monitor com-
munity-based testing. According to the latest data ca 
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20% of the new HIV cases in the region were diagnosed 
within the network.
Alison Brown (Public Health England), Cary James 
(Terence Higgins Trust) and Ann Sullivan (Chelsea and 
Westminster Hospital) presented on the challenges and 
opportunities for expanded testing in the UK in the con-
text of high rates of undiagnosed and late diagnosis of 
HIV. New testing guidelines developed by the National 
Institute for Health and Care Excellence (NICE), to be 
released in December 2016, recognise the importance 
of expanding HIV testing outside of traditional set-
tings. Innovative approaches such as home sampling 
and self-testing have great potential, with one initia-
tive managing to distribute ca 4,000 self-tests in only 
10 days in the country. A majority of those using the 
tests shared their results afterwards, providing a posi-
tive indication in terms of monitoring opportunities of 
this testing approach.
Key points identified through the presentations and 
ensuing discussion included:
• Taking a pragmatic approach and making use of read-
ily available data, including surveillance and program-
matic data are highly important.
• Better estimates of key population size, their geo-
graphic distribution within countries, and the relative 
proportion of undiagnosed cases are crucial to target 
testing services.
• The substantial contribution of community-based 
testing in detecting new HIV cases where it has been 
introduced at scale, e.g. Spain, France, Greece and 
Portugal, was recognised. It was noted that, while 
community testing sites often generate good monitor-
ing data, the lack of consistency in the metrics used 
across single sites undermines the ability to estimate 
the relative contribution to overall testing efforts in 
a country, with some notable exceptions at national 
(e.g. Rede de Rastreio, http://www.gatportugal.org/
noticias/rede-de-rastreio-comunitaria-resultados_83, 
Portugal), sub-national (e.g. the HIV-DEVO Project, 
Spain) and European level (HIV community-based test-
ing practices in Europe [HIV-COBATEST] network) (8).
Existing efforts to monitor HIV testing
Representatives from three countries and two EU pro-
jects presented their experiences in monitoring HIV 
testing: Magdalena Pylli (Hellenic Centre for Diseases 
Control and Prevention, Greece), Kristi Rüütel (National 
Institute for Health Development, Estonia) and Daniel 
Simões (Grupo de Ativistas em Tratamentos (GAT), 
Portugal); Dorthe Raben (Optimising testing and link-
age to care for HIV (OptTEST: http://opttest.eu/)) and 
Laura Fernàndez-López (Operational knowledge to 
improve HIV early diagnosis and treatment among vul-
nerable groups in Europe (Euro HIV-EDAT: https://euro-
hivedat.eu/)). There were substantial similarities in the 
metrics collected for monitoring HIV testing across the 
presentations, the most common being the number of 
screening tests, confirmatory assays, positive tests, 
reason(s) for testing, sex, age and site/setting (e.g. 
laboratory, community site, hospital, ante-natal care 
services). Other metrics were additional socio-demo-
graphic data, previous testing history, risk behaviour 
and risk exposure, knowledge and use of biomedi-
cal HIV prevention (e.g. Post-Exposure Prophylaxis), 
linkage to care, cost per test and cost per diagnosis. 
Furthermore, measuring the rate at which service pro-
viders offer HIV test to eligible patients was deemed a 
key monitoring element for indicator-condition guided 
testing(9).
A number of data sources were mentioned, includ-
ing reference laboratories and primary laboratories, 
health facilities, hospitals, national health insur-
ance databases, cross-sectional and ad hoc studies, 
national and international networks of community-
based testing sites that collect monitoring data using 
online platforms [8]. Among the challenges, poor data 
quality, uncertainty around representativeness of the 
data, limited availability and implementation of qual-
ity control measures were mentioned by all presenters. 
Lack of integration with national monitoring data was 
identified as a major challenge for community-based 
and indicator-condition guided testing initiatives. 
Additional challenges identified included: (i) tracking 
retesting by the same individual, (ii) lack of demo-
graphic data from anonymous tests, and (iii) the (lack 
of) reporting culture among service providers and lim-
ited financial resources.
Suitable metrics and data sources for 
monitoring HIV testing in the EU/EEA
In working groups, participants focused on suitable 
metrics and data sources for monitoring HIV testing in 
the EU/EEA.
Key recommendations concerning metrics and data 
sources included:
• Promote the use of a limited number of metrics that 
can be easily and widely tracked. There was general 
consensus around four metrics: (i) number of tests, (ii) 
basic demographic data of the tester (e.g. age, sex and 
population group), (iii) location/setting of the test, and 
(iv) number of reactive/positive tests.
• Use existing data sources to limit additional burden. 
While the exact data sources will vary by country, exist-
ing ones should be able to generate the data for the 
core metrics.
• Integrate all applicable data in a country to produce 
meaningful national datasets that capture the activities 
of the various organisations conducting HIV tests. The 
critical example is the integration of national monitor-
ing data with those generated from community-based 
testing sites. It was suggested to promote collation 
of community-based organisations’ data at country 
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level as a first step towards effective integration with 
national data.
• Determine how to integrate data on home sampling 
and self-testing into the monitoring approach. One sug-
gestion was to work with industry/private sector to col-
lect indicative (e.g. sales) data.
The participants agreed that the core metrics should 
be scalable and flexible. In terms of scalability, the 
metrics would need to be feasible and meaningful to 
collect at the site level (e.g. by contributing to quality 
improvement cycle) but could also be scaled up for use 
at national and international levels with a comparable 
level of usefulness. They should also be flexible to 
allow use in specific settings and with specific popula-
tions, such as a network of community-based testing 
sites serving MSM or of health facilities implementing 
indicator-condition guided testing which can collect, 
aggregate and compare data points from these metrics 
to assess the implementation and effectiveness of the 
initiatives.
Several other metrics were identified as potentially 
useful for monitoring HIV testing, including linkage to 
care, site/setting of first reactive test/diagnosis, and 
reason for test. Linkage to care was recognised to be 
a vital data point for community organisations to moni-
tor the ability of effectively referring to care of newly 
diagnosed individuals. There was general agreement 
that site/setting of first reactive test and/or diagnosis 
could be collected as an additional variable within the 
European HIV surveillance dataset to gather informa-
tion on testing sites (as a proxy for testing modalities) 
and their relative yield of positive diagnoses.
While there was consensus that key populations’ size 
estimates and relative undiagnosed fractions would be 
extremely valuable instruments to monitor impact of 
testing programmes, there were concerns about their 
accuracy and robustness. The ECDC HIV modelling tool 
[9] [10] [8] is a valuable asset in supporting Members 
States with a standardised method and an easy-to-use 
online tool to produce national estimates. Data on late 
HIV diagnoses and the relative proportion among key 
populations were considered complementary metrics 
that could effectively inform targeted interventions.
Conclusions
Expanding the availability and improving the target-
ing of HIV testing will reduce the percentage of late 
HIV diagnoses as well as the overall number of undi-
agnosed cases in EU/EEA countries. Among the inno-
vative modalities of HIV testing, self-sampling and 
self-testing programmes as well as community-based 
voluntary counselling and testing have been shown to 
expand availability and improve targeting of HIV test-
ing, particularly among key populations who are most 
affected by HIV.
Improving testing policies, planning, resource allo-
cation and programme performance needs timely, 
accurate and high-quality data on HIV testing locally, 
nationally and regionally. Continuous efforts in devel-
oping accurate and robust estimates of people liv-
ing with HIV, the size of key populations and relative 
undiagnosed fractions should be pursued to enable 
better assessment of the impact of testing activities. 
Increasing the utility of already collected metrics, such 
as the proportion of late diagnoses, could effectively 
help targeting testing efforts to key sub-groups.
A small, core set of metrics that are straightforward to 
collect and are broadly useful have been identified and 
should strengthen the capacity to monitor and evalu-
ate testing programmes at local, national and regional 
levels. Data from the full range of national HIV test-
ing initiatives, particularly healthcare and community 
activities, should be routinely aggregated where avail-
able to ensure that countries have a complete picture 
of their situation. The ongoing separation of datasets 
undermines the ability of all stakeholders to under-
stand and assess the opportunities and challenges 
facing HIV testing programmes.
*Erratum
The author name of David Hales was added on 6 December 
2016.
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